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AbstrACt
Objective To investigate the relationship between amyloid 
burden and frequency of existing and incidence of new 
neuropsychiatric symptoms (NPS) in elderly with and 
without cognitive decline.
Methods 275 cognitively normal controls (NC), 100 
subjective memory complaint (SMC), 559 mild cognitive 
impairment (MCI) and 143 Alzheimer’s disease dementia 
subjects from the Alzheimer’s Disease Neuroimaging 
Initiative received (18F)- florbetapir positron emission 
tomography (PET) scans. Yearly neuropsychiatric inventory 
(Neuropsychiatric Inventory (NPI)/NPI- Questionnaire) data 
were collected from the study partners at each visit. Mean 
standard uptake volume ratios (SUVR) normalised to whole 
cerebellum were obtained. Positive amyloid PET scan was 
defined as mean SUVR ≥1.17. Fisher’s exact test was used 
to compare frequency and incidence between amyloid 
positive and amyloid negative subjects. Survival analyses 
were used to estimate of neuropsychiatric symptoms (NPS) 
between amyloid positive and amyloid negative subjects. 
Survival analyses were used to estimate hazard ratios for 
developing the most common NPS by amyloid status.
results No differences in NPS frequency were seen 
between amyloid positive and amyloid negative NC, 
SMC, MCI or dementia groups. MCI subjects with amyloid 
pathology however tended to have greater frequency 
x severity (FxS) of anxiety, hallucinations, delusions, 
apathy, disinhibition, irritability, aberrant motor behavior, 
and appetite, but not agitation, depression, night- time 
disturbances, or elation. MCI subjects with amyloid 
pathology were at greater risk for developing apathy, 
anxiety and agitation over time. Baseline presence of 
agitation and apathy and new onset agitation, irritability 
and apathy predicted faster conversion to dementia among 
MCI subjects.
Conclusions Amyloid pathology is associated with greater 
rate of development of new NPS in MCI. Anxiety and 
delusions are significant predictors of amyloid pathology. 
Agitation, irritability and apathy are significant predictors 
for conversion from MCI to dementia.
bACkgrOund
Alzheimer’s disease (AD) is the most common 
form of dementia, accounting for 60% to 80% 
of all dementia cases. AD is characterised 
by cortical amyloid plaque and neurofibril-
lary tangle deposition, as well as progressive 
synaptic and neuronal loss. Recently devel-
oped amyloid positron emission tomography 
(PET) radioligands with high affinity for 
amyloid plaques, such as (18F)- florbetaben, 
(18F)- flutemetamol and (18F)- florbetapir, 
can provide reliable in vivo visualisation of 
cortical fibrillar β-amyloid plaque deposi-
tion.1–3 With amyloid accumulation begin-
ning up to two decades prior to symptoms 
onset, these amyloid PET radiotracers can 
strength and limitations of this study
 ► Our analyses used Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) data; ADNI - the pre-
mier longitudinal biomarker study in Alzheimer’s 
disease (AD), employs standardised subject assess-
ment and MRI and positron emission tomography 
scan collection protocols and meticulous data quali-
ty control across all study sites.
 ► A strength of our study is the relatively large sample 
size and the inclusion of all diagnostic groups across 
the AD spectrum including cognitively normal partic-
ipants many of which are in the presymptomatic AD 
stages, as well as the use of neuropsychiatric data 
collection tools that are administered to the caregiv-
ers and not the subject themselves.
 ► One of the limitations of this study is that 
the NeuropsychiatricInventory (NPI) and NPI- 
Questionnaire use structured questions focused on 
the frequency and severity of symptoms from the 
preceding month only. Therefore, intermittent neu-
ropsychiatric symptoms that were not manifested by 
the subjects in the prespecified timeframe are not 
adequately captured.
 ► Another limitation to our study is that ADNI employs 
rigorous exclusion criteria typical of clinical trials 
and hence our study cohort might not be represen-
tative of the general population.
 ► ADNI excludes subjects with preexisting depression 
(Geriatric Depression Scale score >5) which like-
wise could affect the generalisation of the results.
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measure amyloid burden in the symptomatic, as well as 
the asymptomatic stages.4 5
Neuropsychiatric symptoms (NPS) are prominent 
features of AD and mild cognitive impairment (MCI) 
and 35% to 75% of MCI subjects experience at least one 
neuropsychiatric symptom with depression, apathy and 
anxiety being the most prevalent.6–8 In the dementia 
stage, apathy, agitation and anxiety are most prevalent, 
followed by aberrant motor behaviour, dysphoria and 
disinhibition.7 9
NPS have been associated with higher likelihood for 
cognitive decline. Symptoms of depression, irritability 
and agitation were found to predict cognitive decline 
among cognitively normal, MCI, as well as individuals 
with subjective cognitive concerns pooled together.10 
One population- based study found that the presence of 
symptoms such as agitation, apathy, anxiety, irritability 
and depression in normal controls (NC) at baseline 
significantly predicted incident MCI.11 Neuroticism and 
its underlying facets of anxiety, depression and stress were 
associated with diagnosis of MCI and neurodegenera-
tion.12 Other studies have shown that the presence of one 
or more NPS in MCI, specifically symptoms of agitation, 
depression and apathy, increase the risk of progression 
from MCI to AD dementia.10 13–19 Most patients with AD 
experience at least one NPS during the course of disease 
progression.6 NPS in dementia are associated with faster 
disease progression,20 21 increased mortality15 and care-
giver burden,22 as well as shorter time until nursing home 
admission.23 24
To date a few groups have studied the associa-
tions between NPS and amyloid burden and some 
have suggested that NPS reflect underlying amyloid 
pathology.25 26 Studies have gone on to show that 
increased apathy was significantly associated with greater 
cortical amyloid burden in MCI.27 Anxious MCI subjects 
were 3.1 times more likely to have abnormal cerebro-
spinal fluid amyloid β levels — a proxy marker for brain 
amyloidosis.28 Another group found both anxiety and irri-
tability to associate with greater amyloid burden across 
the AD spectrum.29 Amyloid positive NC who reported 
anxiety experienced faster cognitive decline30 and greater 
frequency of mood disturbances over the following year.31 
Taken together these data seem to suggest that at least 
some NPS are associated with amyloid pathology and 
cognitive decline.
Here we investigate the relationship between amyloid 
burden and incidence and frequency of NPS across the 
spectrum from normal cognition to dementia. We hypoth-
esised that amyloid pathology will associate with higher 
incidence of NPS across all disease stages. We postulated 
that amyloid deposition will associate with apathy, anxiety, 
irritability and depression in the asymptomatic and early 
symptomatic stages, and with psychosis, aberrant motor 
behaviours, disinhibition and agitation in the late symp-
tomatic stages.
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Figure 1 De novo emergence of neuropsychiatricsymptoms by diagnosis and amyloid status. Note: y- axis vary by diagnosis.
MethOds
subjects
Data used in these analyses were obtained from the Alzhei-
mer’s Disease Neuroimaging Initiative (ADNI) database 
( adni. loni. usc. edu). The ADNI was launched in 2003 as 
a public- private partnership. The primary goal of ADNI 
has been to test whether serial MRI, PET, other biological 
markers and clinical and neuropsychological assessment 
can be combined to measure the progression of MCI and 
early AD.
The first phase of ADNI, ADNI-1, recruited approx-
imately 800 adults, ages 55 to 90 across 50 sites in the 
USA and Canada. The study sample consisted of approx-
imately 200 older NC individuals, 400 people with late 
amnestic MCI (LMCI) and 200 people with mild AD. 
ADNI expanded enrolment criteria with the launch of 
ADNI- GO in 2009 and enrolled 200 additional subjects 
with early amnestic MCI (EMCI). ADNI-2 added approxi-
mately 650 newly enrolled subjects (150 NC, 100 subjects 
with subjective memory complaints (SMC), 100 EMCI, 150 
LMCI and 150 mild AD). All procedures were approved 
by the Institutional Review Boards of all participating 
institutions. Written informed consent was obtained from 
every research participant according to the Declaration 
of Helsinki and the Belmont Report.
The clinical description of the ADNI cohort has been 
previously published.32 Diagnosis of AD was based on the 
National Institute of Neurological and Communicative 
Disorders and Stroke and the AD and Related Disorders 
Association criteria.33 AD subjects were required to have 
Mini- Mental State Examination (MMSE)34 scores between 
20 and 26 and a Clinical Dementia Rating scale (CDR)35 
score of 0.5 to 1 at baseline. Qualifying MCI subjects had 
memory complaints, but no significant functional impair-
ment, scored between 24 and 30 on the MMSE, had a 
global CDR score of 0.5, a CDR memory score of 0.5 or 
greater and objective memory impairment on Wechsler 
Memory Scale – Logical Memory II test.36 NC and SMC 
subjects had MMSE scores between 24 and 30, a global 
CDR of 0 and did not meet criteria for MCI and AD. NC 
were devoid of cognitive concerns, while SMC subjects 
had significant memory concerns manifested in a score of 
≥16 on the first 12 items of the Cognitive Change Index.37 
Subjects were excluded if they refused or were unable to 
undergo MRI, had other neurological disorders, active 
depression or history of psychiatric diagnosis, alcohol 
or substance dependence within the past 2 years, less 
than 6 years of education or were not fluent in English 
or Spanish. Inclusion and diagnostic criteria, as well as 
procedures and protocols, for the ADNI studies can be 
found on http://www. adni- info. org/ Scientists/ ADNI-
StudyProcedures. html. Written informed consent was 
obtained from all participants. For more up- to- date infor-
mation, see www. adni- info. org.
(18F)- florbetapir PET amyloid imaging was added in 
the ADNI- GO/2 stages of the study. We downloaded the 
clinical, behavioural and amyloid PET data of 275 NC, 
100 SMC, 559 MCI and 143 AD subjects from the ADNI-1, 
ADNI- GO and ADNI-2 databases on 3 November, 2015. 
EMCI and LMCI were grouped in our analyses.
neuropsychiatric data
Neuropsychiatric data were captured with the Neuropsy-
chiatric Inventory (NPI)38 and the NPI Questionnaire 
(NPI- Q).39 ADNI-1 used the NPI- Q while ADNI- GO/2 
used the full version. Both versions assess 12 symptoms 
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Figure 2 Survival curves showing time to emergence of the five most frequent early neuropsychiatricsymptoms in mild 
cognitive impairment by amyloid status.
— delusions, hallucinations, agitation, anxiety, apathy, 
irritability, depression, euphoria, disinhibition, aberrant 
motor behaviour, sleep and appetite. Interviewers ask 
structured questions about the presence and severity (as 
well as frequency in the full version of the NPI, but not in 
NPI- Q) of the symptoms in the past month to the study 
partner. Those enrolled in ADNI-1 only had the NPI- Q 
available, while those enrolled in ADNI-2 and ADNI- GO 
were administered the full version.
NPI or NPI- Q data from the baseline and all annual 
visits were obtained from the Laboratory of Neuroim-
aging Image Data Archive (LONI IDA) on 3 November, 
2015. Each patient had either NPI or NPI- Q for each visit 
that was analysed. NPS at baseline were coded as ‘absent’ 
if not endorsed and as ‘present’ if endorsed by the study 
partner. In our longitudinal analyses, we coded symptoms 
in follow- up as ‘absent’ if never endorsed by the study 
partner (including the baseline visit) and as ‘emerging 
de novo’ if absent at baseline but reported at one or more 
follow- up visit. Frequency x severity (FxS) scores were 
obtained for subjects that received the full NPI question-
naire at baseline.
Imaging data and analysis
A detailed description of AV-45 PET acquisition may be 
found at http://www. adni- info. org/ Scientists/ ADNIS-
tudyProcedures. html. Briefly, 370 MBq (10 mCi +/-10%) 
bolus injection of AV-45 was administered intravenously. 
Approximately 50 min after injection, a 20 min contin-
uous brain PET imaging session collected a dynamic 
amyloid PET data consisting of four 5 min frames. In 
our main analyses, we used the mean whole brain stan-
dard uptake volume ratios (SUVR) from University of 
California, Berkeley (UCB), downloaded from ADNI’s 
database on 3 November, 2015. The mean whole brain 
SUVR was obtained by averaging the SUVR values across 
5Goukasian N, et al. BMJ Open 2019;9:e031947. doi:10.1136/bmjopen-2019-031947
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Figure 3 Survival curves showing the effect of the presence of the five most frequent early neuropsychiatricsymptoms on time 
to conversion from mild cognitive impairment to dementia.
the frontal, anterior/posterior cingulate, lateral parietal 
and lateral temporal grey matter regions.40 The UCB 
protocols for (18F)- florbetapir preprocessing, co- registra-
tion and normalisation have been previously described.40 
We defined a positive amyloid PET scan as mean SUVR 
≥1.17.41
statistical analyses
Demographic comparisons between amyloid positive and 
amyloid negative groups within diagnostic categories 
were done using Fisher’s exact for categorical variables 
and Wilcoxon rank- sum test for continuous variables. 
Comparisons of the frequency of symptoms at baseline, 
as well as the emergence of new NPS in follow- up condi-
tional on amyloid status were done using Fisher’s exact 
test. Using stepwise backwards logistical regression we 
also studied the predictive value of the presence/absence 
of NPI behaviours as well as their FxS scores on amyloid 
status while adjusting for age, sex, education and Apoli-
poproteinE ε4 (APOE4).
Survival analyses using Cox proportional hazard regres-
sion models were used to determine (1) the hazard ratios 
for developing the five most common early NPI symptoms 
— apathy, anxiety, agitation, irritability and depression 
— in amyloid positive versus amyloid negative partici-
pants in the NC, SMC and MCI groups; (2) the hazard 
for conversion from MCI to dementia in all MCI subjects 
based on the presence of the top five most common early 
NPI symptoms at baseline and (3) the hazard for conver-
sion from MCI to dementia in MCI subjects who were free 
of the five most common NPI symptoms at baseline but 
developed them in follow- up. For analyses (2) and (3), 
subsequent visits were excluded once a subject was diag-
nosed with dementia. Subjects who reverted from MCI to 
NC (n=34) in follow- up were excluded from all analyses. 
We censored the data ignoring visits after dementia was 
diagnosed in our time to conversion Cox proportional 
hazard regression models. All Cox proportional hazard 
regression models were adjusted for age, education and 
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Figure 4 Survival curves showing the effect of de novo development of the five most frequent early neuropsychiatric 
symptoms on time to conversion from mild cognitive impairment to dementia.
APOE4 status. The Cox regression models were repeated 
while additionally adjusting for amyloid status. P values 
were adjusted for multiple comparisons using false 
discovery rate (FDR). All Cox regression models were 
evaluated for proportional hazard assumption and there 
was no evidence that the models did not meet required 
assumptions (q- value >0.081). All p values were adjusted 
for multiple comparison correction using Benjamini & 
Hochberg42 FDR correction. All statistical tests were two- 
sided and a q- value less than 0.05 was considered statisti-
cally significant. All statistical analyses were done in the 
R Statistical Computing Environment (R Core Team, 
Vienna, Austria).
Patient and public involvement
Our study represents secondary analyses of preexisting 
data. Patients or the public were not engaged in defining 
our research questions and outcome measures and have 
not provided input into study design and conduct of this 
study. A yearly manuscript summarising all findings from 
the ADNI study is published by the ADNI leadership 
team.43–45 As our analyses use deidentified data only, study 
participants will not be contacted with these findings.
results
Our sample consisted of a total of 1077 ADNI subjects 
including 275 NC (26.5% amyloid positive), 100 SMC 
(28.0% amyloid positive), 559 MCI (52.0% amyloid posi-
tive) and 143 AD (82.5% amyloid positive) subjects with 
average follow- up time of 3.2±2.4 years (table 1). Amyloid 
positive NC and SMC were significantly older and more 
likely to be APOE4 positive relative to their amyloid 
negative counterparts. Amyloid positive NC were also 
less educated and performed worse on the Alzheimer’s 
7Goukasian N, et al. BMJ Open 2019;9:e031947. doi:10.1136/bmjopen-2019-031947
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Disease Assessment Scale – Cognition Subscale 11 
(ADAScog-11) compared with amyloid negative NC. 
Amyloid positive MCI were significantly older, more likely 
to be APOE4 positive, and showed greater impairment 
on MMSE, Clinical Dementia Rating – Sum of Boxes, 
ADAScog-11 and Functional Assessment Questionnaire 
scales compared with amyloid negative MCI. Amyloid posi-
tive dementia subjects were more likely to be APOE4 posi-
tive, and showed greater impairment on the ADAScog-11 
compared with the amyloid negative dementia subgroup. 
No significant difference in years of follow- up was seen 
between the amyloid positive versus negative subjects in 
each of the diagnostic groups (table 1).
neuropsychiatric symptoms at baseline
No differences in NPS frequency at baseline were seen 
between amyloid positive and amyloid negative NC, SMC, 
MCI or dementia groups (online supplementary table 1). 
Comparing NPI FxS means between the amyloid positive 
and negative subgroups within each diagnostic group 
revealed significantly greater aberrant motor behaviours 
FxS in amyloid positive versus amyloid negative NC (0.083 
vs 0.005, p=0.04). Compared with amyloid negative MCI, 
amyloid positive MCI manifested significantly greater 
anxiety FxS (0.569 vs 0.314, p=0.023), delusions FxS 
(0.138 vs 0.004, p=0.001) and aberrant motor behaviours 
FxS (0.286 vs 0.088, p=0.025). Compared with amyloid 
negative dementia subjects, amyloid positive dementia 
cases showed significantly lower apathy FxS (1.271 vs 
2.583, p=0.011), agitation FxS (0.619 vs 1.708, p=0.003) 
and appetite changes (0.864 vs 2.417, p=0.006), however 
these findings should be cautiously interpreted due to the 
very small sample size of the amyloid negative dementia 
group (n=25 vs n=118 amyloid positive). No significant 
differences were seen in SMC. The full statistical models 
can be seen in online supplementary table 2.
Cumulative incidence of nPs in follow-up
No differences in the rates of de novo development of 
NPS were seen between amyloid positive and amyloid 
negative subjects in the NC, SMC or dementia groups. 
New onset delusions (13.4% vs 2.2%, p<0.001), hallucina-
tions (8.0% vs 2.2%, p=0.007), anxiety (35.9% vs 24.8%, 
p=0.014), apathy (38.4% vs 21.8%, p<0.001), disinhi-
bition (24.2% vs 14.7%, p=0.014), irritability (45.5% vs 
32.7%, p=0.014), aberrant motor disturbances (18.1% 
vs 9.2%, p=0.008) and appetite disturbances (33.5% 
vs 20.9%, p=0.007) were significantly more common in 
amyloid positive versus amyloid negative MCI (figure 1). 
The full statistical models can be seen in online supple-
mentary table 3.
Predictors of amyloid status at baseline
In our pooled stepwise backwards logistic regression 
model, anxiety (OR=1.87, 95% CI 1.17 to 3.02, p=0.018) 
and delusions (OR=7.01, 95% CI 1.25 to 132.05, p=0.04) 
were predictive of amyloid positivity after adjusting for 
age, sex, education and APOE4 in the pooled sample. 
When we analysed the same relationship using the contin-
uous FxS measure, delusions were a significant predictor 
(OR=2.22, 95% CI 1.18 to 6.23, p=0.012).
Among MCI participants the presence of anxiety 
(OR=1.77, 95% CI 1.03 to 3.09, p=0.04) at baseline was 
predictive of AD pathology. Using the continuous FxS 
measure revealed significant association between delu-
sions and amyloid pathology (OR=5.8, 95% CI 1.69 to 
98.36, p=0.001).
No significant differences were seen among the indi-
vidual NC, SMC or dementia groups.
time to development of the five most frequent early nPs by 
amyloid status
Here we focused on the five most common early NPS — 
apathy, anxiety, agitation, irritability and depression. Time 
to de novo development of these NPS in NC and SMC did 
not differ by amyloid status. After adjusting for age, educa-
tion and APOE4 status, amyloid pathology in MCI was 
associated with faster emergence of agitation (HR=1.47, 
95% CI 1.09 to 1.99, p=0.012), anxiety (HR=1.45, 95% CI 
1.07 to 1.98, p=0.017) and apathy (HR=1.34, 95% CI 0.98 
to 1.83, p<0.001) (figure 2).
effect of baseline nPs on time to conversion in MCI
Individually, adjusting for age, education and APOE4 
status, four of the five early NPS at baseline were signifi-
cantly associated with time to conversion from MCI 
to dementia (agitation HR=2.28, 95% CI 1.64 to 3.17, 
p<0.001; depression HR=1.51, 95% CI 1.08 to 2.11, 
p=0.021; irritability HR=1.88, 95% CI 1.35 to 2.63, 
p<0.001; anxiety HR=1.39, 95% CI 0.96 to 2.02, p=0.083; 
apathy HR=2.69, 95% CI 1.92 to 3.78, p<0.001). Addi-
tionally, adjusting for amyloid status did not change the 
results (agitation HR=1.78, 95% CI 1.27 to 2.49, p=0.002; 
depression HR=1.44, 95% CI 1.03 to 2.02, p=0.04; irri-
tability HR=1.61, 95% CI 1.15 to 2.25, p=0.009; anxiety 
HR=1.2, 95% CI 0.82 to 1.75, p=0.341; apathy HR=2.57, 
95% CI 1.83 to 3.61, p<0.001).
When all five symptoms were entered simultaneously 
into a multivariable Cox regression model adjusting for 
age, education and APOE4 status agitation and apathy 
remained significant (agitation HR=1.76, 95% CI 1.19 
to 2.6, p=0.005; apathy HR=2.59, 95% CI 1.81 to 3.71, 
p<0.001). After additionally adjusting for baseline 
amyloid status apathy remained significant (agitation 
HR=1.46, 95% CI 0.99 to 2.15, p=0.057; apathy HR=2.48, 
95% CI 1.73 to 3.56, p<0.001) (figure 3).
effect of de novo nPs on time to conversion in MCI
Individually, adjusting for age, education and APOE4 
status, the emergence of agitation, depression, anxiety 
and apathy were associated with greater risk for conver-
sion from MCI to dementia (agitation HR=2.17, 95% CI 
1.47 to 3.2, p<0.001; depression HR=1.54, 95% CI 1.02 
to 2.33, p=0.049; anxiety HR=2.17, 95% CI 1.47 to 3.2, 
p<0.001; apathy HR=2.33, 95% CI 1.57 to 3.45, p<0.001). 
Agitation, anxiety and apathy remained significant when 
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we also adjusted for amyloid status (agitation HR=2.03, 
95% CI 1.37 to 3, p=0.001; anxiety HR=2.03, 95% CI 
1.37 to 3, p=0.001; apathy HR=2.42, 95% CI 1.65 to 3.57, 
p<0.001).
When all five symptoms were entered simultaneously 
into a multivariable Cox regression model adjusting for 
age, education and APOE4 status, de novo agitation, irrita-
bility and apathy were significant predictors of conversion 
from MCI to dementia (agitation HR=2.0, 95% CI 1.17 to 
3.43, p=0.012; irritability HR=0.45, 95% CI 0.24 to 0.82, 
p=0.009; apathy HR=2.09, 95% CI 1.17 to 3.73, p=0.012). 
Additionally, adjusting for baseline amyloid status, did 
not change the results (agitation HR=1.91, 95% CI 1.12 
to 3.28, p=0.018; irritability HR=0.47, 95% CI 0.26 to 0.86, 
p=0.014; apathy HR=2.42, 95% CI 1.39 to 4.23, p=0.002) 
(figure 4).
dIsCussIOn
Here we investigated the relationship between amyloid 
burden and incidence and frequency of NPS across 
the spectrum from normal cognition to dementia. We 
hypothesised that amyloid pathology will associate with 
higher frequency of NPS across all disease stages, but we 
found that while the frequency of NPS is not significantly 
different between amyloid negative and positive diag-
nostic groups, some NPS might be more severe in those 
who are amyloid positive (online supplementary table 
2). This held true for aberrant motor behaviours among 
amyloid positive NC and MCI, as well as anxiety and delu-
sions in amyloid positive MCI. Our findings in the MCI 
group is in line with those by Krell- Roesch et al, 2019, 
who found that compared with MCI and NC without 
amyloid burden, MCI with amyloid burden but not NC 
with amyloid burden had an increased risk of having 
NPS.26 Looking into whether neuropsychiatric symptoms 
carry prognostic value of Alzheimer’s pathology we found 
anxiety to be predictive of brain amyloidosis in the pooled 
and MCI samples. Delusions carried additional predictive 
value in MCI.
In line with our hypothesis, a greater proportion of the 
amyloid positive MCI had emergence of delusions, hallu-
cinations, anxiety, apathy, disinhibition, irritability, aber-
rant motor behaviours and appetite changes compared 
with amyloid negative MCI over the course of the study 
(figure 1). These findings are as expected considering 
the prominence and progressive development of NPS 
over time during the course of the disease.6 7 Our Cox 
proportional hazard regression model further demon-
strated that participants with MCI due to AD develop 
apathy, anxiety and agitation — three of the earliest and 
most pervasive NPS in the MCI stage, earlier compered to 
amyloid negative MCI (figure 2).6
Contrary to our expectations we found that amyloid 
negative dementia subjects have higher frequency of 
apathy, agitation and appetite changes compared with 
the amyloid positive dementia group. One possible expla-
nation is that previous studies on the prevalence of NPS 
in AD dementia have not included biomarker validation. 
This means that AD phenocopies with amnestic presen-
tation were included as AD cases. ADNI is the first large 
scale observational study that included amyloid PET as 
a biomarker. Thus, for the first time we have the oppor-
tunity to investigate the frequency of NPS in biomarker 
validated AD dementia and compare that to AD pheno-
copies. What we find here suggests that these previous 
reports might have overestimated the true prevalence 
of some NPS in AD dementia due to including amyloid 
negative AD phenocopies in the AD dementia group. 
An alternative explanation is that ADNI subjects who are 
amyloid negative have other neurodegenerative disorders 
such as frontotemporal dementia, dementia with Lewy 
bodies, argyrophilic grain disease, hippocampal sclerosis, 
etc. These other pathological entities could also explain 
the increased frequencies of NPS.
The survival analyses looking into the effects of the 
five most frequent early NPS on time to conversion from 
MCI to dementia showed that four of the five early NPS 
symptoms — agitation, apathy, depression and irritability, 
were individually predictive of conversion from MCI to 
dementia as previously reported.10 13–19 Of these agitation 
and apathy remained significant when adjusting for the 
presence of all five behaviours as previously reported.13 14 17
When we focused on the predictive effects of newly 
emerging symptoms on future conversion from MCI to 
dementia, four of the five symptoms — agitation, depres-
sion, anxiety and apathy, were individually predictive. 
Agitation, irritability and apathy proved to be the main 
drivers of this relationship when adjusting for the pres-
ence of all five behaviours.
Taken together our data seem to indicate that both 
prevalent agitation, and apathy, and incident agitation, 
irritability and apathy are predictive of faster functional 
decline and loss of independence among amyloid posi-
tive and negative MCI. Our findings regarding agitation 
seem to agree with those reported by Brodaty et al13 who 
also found that agitation was significantly associated with 
cognitive decline. Several studies have also concluded that 
apathy is a useful NPS for identifying cognitive decline 
to AD.18 46 Affective symptoms, including irritability, have 
also been previously reported in association with later 
cognitive decline to dementia.47
Contrary to our expectations and the observations of 
others11 30 NPS were not associated with faster cognitive 
decline among ADNI’s amyloid positive NC. We could 
hypothesise that both the sample size differences (n=275 
in our study vs n=1587 in the large population- based study 
by Geda et al11) as well as the different inclusion criteria 
used by these two studies (ie, the mandatory lack of even 
perceived age- associated decline and the exclusion of 
individuals with baseline depression defined as Getriatric 
Depression Scale (GDS) >5 in ADNI NC) and the fact 
that Geda et al did not have information regarding brain 
amyloidosis, as potential drivers for these differences.
Several strengths and limitations of the ADNI study 
should be acknowledged. One of the strengths of this 
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study is our cohort. ADNI is the premier longitudinal 
biomarker study in AD. ADNI employs unified subject 
assessment and PET scan collection protocols and metic-
ulous data quality control across all study sites. Another 
strength of our study is the relatively large sample size 
and the inclusion of all diagnostic groups across the AD 
spectrum instead of just the symptomatic ones as it has 
been done in the past. Another strength of our paper 
is the use of neuropsychiatric data collection tools that 
are administered to the caregivers and not the subject 
themselves. One of the limitations of this study is that the 
NPI and NPI- Q use structured questions focused on the 
presence and severity of symptoms from the preceding 
month only, and therefore, intermittent NPS that were 
not manifested by the subjects in the prespecified time-
frame were not captured. Another limitation to our study 
is that ADNI employs rigorous exclusion criteria typical 
of clinical trials and the study population and hence our 
study cohort might not be representative of the general 
population. Moreover, ADNI criteria excludes subjects 
with GDS greater than or equal to five and any primary 
psychiatric condition. These selection criteria undoubt-
edly have further influenced on our study and might limit 
the overall generalisability of our findings to the elderly 
population as a whole. Lastly, since the model selection 
and model building were done in the same data set, our 
results are considered explanatory. Further studies are 
warranted to confirm our results.
In summary, we investigated the relationship between 
amyloid burden and occurrence of NPS in elderly with 
and without cognitive decline at baseline and over time. 
We found that amyloid pathology is a significant risk factor 
for future development of NPS in MCI, but not in the 
presymptomatic or at- risk stages of the disease. We also 
found that the presence of apathy, agitation, depression 
and irritability in MCI patients predict a more aggressive 
disease course regardless of the presence or absence of 
amyloid pathology.
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